drugset / Trial / NCT05927272

Deciphering the Vitiligo Transcriptomic Signature Between Repigmented and Non Repigmented Lesions

NCT05927272

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to perform an in-depth analysis of the molecular pathways involved in lesions responding to current treatment and lesions not responding to current treatment

Timeline

Start
2024-04-10
Primary completion
2025-10-09
Completion
2025-10-09

Drugs

EvaluationDrugModalityDoseRoute
Background Methylprednisolone Other / unclassified 16 mg Oral

Indications